about
Sympathetic nervous system and chronic bladder pain: a new tune for an old songFrom bladder to systemic syndrome: concept and treatment evolution of interstitial cystitisα1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?TRPV1: a therapeutic target for novel analgesic drugs?Bladder sensory desensitization decreases urinary urgency.Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment.Can the adrenergic system be implicated in the pathophysiology of bladder pain syndrome/interstitial cystitis? A clinical and experimental studySingle-incision sling system as primary treatment of female stress urinary incontinence: prospective 12 months data from a single institution.VEGF signaling mediates bladder neuroplasticity and inflammation in response to BCGCurrent medical treatment of lower urinary tract symptoms/BPH: do we have a standard?Vanilloid receptor and detrusor instability.Biomarkers in overactive bladder: a new objective and noninvasive tool?The role of brain-derived neurotrophic factor (BDNF) in the development of neurogenic detrusor overactivity (NDO).Urinary bladder inflammation induces changes in urothelial nerve growth factor and TRPV1 channels.Biomarkers of fatigue related to adjuvant chemotherapy for breast cancer: evaluation of plasma and lymphocyte expression.Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies.Neurotrophins in the lower urinary tract: becoming of ageMechanisms involved in new therapies for overactive bladder.Botulinum toxin in the management of lower urinary tract dysfunction: contemporary update.TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications.Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms.OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiologyThe ERK 1 and 2 pathway in the nervous system: from basic aspects to possible clinical applications in pain and visceral dysfunction.Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence.Mini-arc for the treatment of female stress urinary incontinence: long-term prospective evaluation by patient reported outcomes.Modulation of urinary bladder innervation: TRPV1 and botulinum toxin A.The medical treatment of overactive bladder, including current and future treatments.Suburethral single incision slings in the treatment of female stress urinary incontinence: what is the evidence for using them in 2010?Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.EAU guidelines on surgical treatment of urinary incontinence.Neurotrophins as regulators of urinary bladder function.Transient receptor potential channels in bladder function.Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms.Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure.Bladder function after radical hysterectomy for cervical cancer.Intrarenal artery pseudoaneurysm after blunt abdominal trauma: a case report of successful superselective angioembolization.Biomarkers in lower urinary tract symptoms/overactive bladder: a critical overview.Biomarkers of spinal cord injury and ensuing bladder dysfunction.
P50
Q26773584-DB2BE845-6401-42C2-98FB-2660C6B8F52BQ26801107-C810F18B-F6B7-4922-BDAD-19D2426B61AAQ28070342-610798A2-5E9A-4060-9509-D2F2A181DF65Q28265119-278C0F5E-7E16-4F75-AF6F-8893EBA74B12Q30832054-8156A3B5-C82D-4BB6-B204-3D9EDB95817CQ30837390-956D279C-B166-421B-95D5-11CF0605EE35Q33493614-D54DB2BD-CA80-4720-88EC-9858D77FF8A6Q33800907-9E560821-B76F-470B-90FF-261CE42A4065Q33860372-C229F252-1743-48D2-9DBE-95F4ED175E8EQ34068680-5A8DB064-CED1-4870-916E-3A3BCCFFBE93Q34385085-95007C21-1538-450F-9D83-79E0F32A5BE5Q34635423-07AE86CC-0E4A-4BA2-ADD8-0CFAC7F06B3BQ35040019-FB0864D6-7FA4-4D56-B527-7F9C2BEEBFFEQ35044823-6E36A2E8-0481-4B9F-8FAF-47D2E8400CA7Q35223911-B4141479-B9C3-4006-BB92-E77D547AFEF7Q35264807-F4C8274F-CA44-436B-8BFF-A99F18EFC7EDQ35510256-B366A09B-1AFD-4E25-90B0-1DF43CC0662FQ35687029-C9DA910E-72CE-4E3B-9D21-337E85C29EFCQ35687993-380F2DE4-EB71-4476-89BF-ECF7D4F07B4BQ35997057-21C7A9C5-1378-4B5B-9ADA-F6650E835A81Q36487773-5C5FB1DF-DE24-45D7-8463-21ED9B1106D7Q36912946-DFF37A31-2249-404D-86C1-29E767CFC67FQ37299990-A3EC8231-597A-41B3-BA63-D45C37502D9BQ37420455-859EF954-F1DA-4BCF-BED1-2CAE7C66A8CDQ37483439-438751FA-5A10-4BCC-8549-179FAD2F3C5DQ37485861-C15F5805-FF2A-4394-9A4F-4786B5A8D82AQ37571029-BEAC26A1-8638-46FC-8333-2A4011483C07Q37835086-8582E30F-E3B7-4B2A-A735-F23FF1E2B6EBQ37836943-EEC87B21-64D3-47E0-8D7E-130FA22F25FCQ37879343-B3422237-2933-455D-A09D-EF53D171CE5DQ38038271-92B14A41-6C40-4E2B-93DD-3CBCB05F014BQ38049685-70AC1FC0-111D-46EE-A831-4C1BC4AE6456Q38050405-2DC24594-6666-4B8B-8CAD-ECC383E466CCQ38056773-52B23811-4CE5-4641-8916-E7EA4B7463B7Q38109747-C22F2DBA-6B89-4722-BE43-4C4609A5CD51Q38182708-64B60884-E3D6-40AD-8F9C-2C3424FA73CAQ38187378-7F202A35-29E9-40AE-9AFA-DB0AE938AC3FQ38210220-97468A7A-CFC7-4B59-ABE1-7E77444A847DQ38212859-B0C2B967-C005-4179-8E3D-655AA77A81BCQ38274945-E25BAF3A-3A6E-450E-BC6B-259038552AF8
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francisco Cruz
@ast
Francisco Cruz
@en
Francisco Cruz
@es
Francisco Cruz
@sl
type
label
Francisco Cruz
@ast
Francisco Cruz
@en
Francisco Cruz
@es
Francisco Cruz
@sl
prefLabel
Francisco Cruz
@ast
Francisco Cruz
@en
Francisco Cruz
@es
Francisco Cruz
@sl
P1153
P106
P1153
55971698400
56468864000
7102657694
P21
P31
P496
0000-0003-4551-514X